| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | VIA; SEMA; HT018; SEMAQ; SEMA6A1 |
| WB Predicted band size | 114 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human SEMA6A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SEMA6A抗体的3篇参考文献及其摘要概括：
1. **文献名称**: "Semaphorin 6A regulates angiogenesis by modulating VEGF signaling through plexin-A2"
**作者**: Casazza A, et al.
**摘要**: 该研究利用SEMA6A抗体阻断实验，揭示SEMA6A通过结合plexin-A2受体抑制血管内皮生长因子(VEGF)信号通路，从而抑制肿瘤血管生成和转移，为靶向治疗提供了新方向。
2. **文献名称**: "SEMA6A controls cranial neural crest migration by regulating integrin activity"
**作者**: Schwarz Q, et al.
**摘要**: 通过免疫组织化学和功能实验(使用SEMA6A抗体)，研究发现SEMA6A在胚胎发育中通过调控整合素活性指导颅神经嵴细胞定向迁移，揭示了其在形态发生中的关键作用。
3. **文献名称**: "SEMA6A promotes glioblastoma progression via TGF-β/Smad3 signaling"
**作者**: Li Y, et al.
**摘要**: 该研究通过Western blot和免疫荧光(使用SEMA6A特异性抗体)证明，SEMA6A在胶质母细胞瘤中高表达，并通过激活TGF-β/Smad3通路促进肿瘤侵袭，提示其作为预后标志物的潜力。
SEMA6A (Semaphorin 6A) is a transmembrane protein belonging to the semaphorin family, which plays critical roles in axonal guidance, cell migration, and tissue development. It contains a conserved Sema domain and immunoglobulin-like folds, enabling interactions with plexin receptors and other signaling components. SEMA6A is involved in neural circuit formation, vascular patterning, and immune regulation, with dysregulation linked to neurodevelopmental disorders, cancer progression, and autoimmune diseases.
Antibodies targeting SEMA6A are essential tools for studying its expression, localization, and function. They are widely used in techniques like Western blotting (WB), immunohistochemistry (IHC), and immunocytochemistry (ICC) to detect SEMA6A in tissues or cultured cells. Research highlights its dual role in cancer: SEMA6A acts as a tumor suppressor in gliomas by inhibiting angiogenesis, yet promotes invasiveness in breast cancer via EMT activation. These context-dependent effects underscore the importance of SEMA6A antibodies in elucidating disease mechanisms.
Commercial SEMA6A antibodies are typically raised against specific epitopes, such as the extracellular Sema domain or cytoplasmic regions. Validation includes knockout controls and functional assays. Beyond basic research, SEMA6A antibodies hold potential for diagnostic applications, as altered SEMA6A expression correlates with patient prognosis in certain cancers. Ongoing studies explore its therapeutic targeting, particularly in neural repair and anti-metastatic strategies.
×
